A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety of gabapentin, as compared to placebo, in a potential over-the-counter population with reports of occasional sleeplessness

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Gabapentin; gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

• Subjects >/= 12 years of age who reported occasional sleeplessness in month prior to screening

Exclusion Criteria:

• Females who were pregnant or breastfeeding